Clovis Oncology (CLVS) Misses Q4 EPS by 10c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. EXPE
5. ARM
6. QCOM
7. DDOG
8. CPAY
9. MCD
10. CHYM

Go back to Clovis Oncology (CLVS) Misses Q4 EPS by 10c

Clovis Oncology Announces 2019 Operating Results

February 24, 2020 4:05 PM EST

Rubraca® (rucaparib) net product revenue totaled $143.0M for 2019 and $39.3M for Q4 2019 Net product revenue for 2019 up 50% over 2018 46% reduction in net cash utilized in 2H 2019 compared to 1H 2019 $296.7M in cash, cash equivalents and available for sale securities at December 31, 2019; continue to anticipate cash runway into 2H 2021 Transaction in January 2020 reduced outstanding convertible debt at year-end 2019 by $123.4M Supplemental NDA for Rubraca in patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer granted Priority Review by FDA with PDUFA date of May 15, 2020 Lucitanib combination studies... More